A carregar...
KRAS G12C inhibition and innate immune targeting
INTRODUCTION: KRAS mutations drive tumorigenesis by altering cell signaling and the tumor immune microenvironment. Recent studies have shown promise for KRAS-G12C covalent inhibitors, which are advancing rapidly through clinical trials. The sequencing and combination of these agents with other thera...
Na minha lista:
| Publicado no: | Expert Opin Ther Targets |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8122058/ https://ncbi.nlm.nih.gov/pubmed/33703985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728222.2021.1902991 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|